Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Besides the first generation Chimeric antigen receptor (CARs), Creative Biolabs also constructs CellRapeutics™ second generation CARs products with high quality. Our skilled scientists have rich experience in constructing CARs of different generations, which offers you the world leading service.
Sjoukje J. C. van der Stegen, Mohamad Hamieh & Michel Sadelain. The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery 14, 499–509 (2015)
Second-generation CARs architecture comprises an antigen binding domain, a hinge or spacer region, a transmembrane domain (TM) and an endodomain. The antigen binding domain is usually derived from a single-chain variable fragment (scFv) which recognizes and binds tumor specific antigens. The hinge domain links the antigen binding domain with TM. It provides sufficient flexibility to facilitate antigen binding. The application of a hinge in CARs is depended on the type of the antigen. With our extensive experience, we can design an appropriate hinge within CARs to achieve an optimal T cell response.
The first generation CARs has only one endodomain (intracellular signaling region) like CD3ζ. It is designed to activate T cell and induce cytolysis. However, it cannot perform a long term response. To overcome this, the second generation CARs which consist of the activating and the co-stimulatory signal domains are designed. Compared to the former generation, this generation CARs compose a single costimulatory region derived from either CD28 or 4-1BB in addition to CD3ζ. In preclinical and early clinical investigations, the second generation CARs have performed more prolonged polyclonal expansion and antitumor effect.
With advanced techniques and seasoned scientists, Creative Biolabs can offer full line of CARs products targeting many malignant tumor antigens. We provide the first-class service which is tailored to meet your needs and goals.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
